Comparison of Effects of ACEIs and ARBs on Albuminuria and Hyperkalemia in Indonesian Hypertensive Type 2 Diabetes Mellitus Patients.
Journal
International journal of hypertension
ISSN: 2090-0384
Titre abrégé: Int J Hypertens
Pays: United States
ID NLM: 101538881
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
11
2019
revised:
14
06
2020
accepted:
30
06
2020
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
18
8
2020
Statut:
epublish
Résumé
Due to economic consideration, Indonesia's formulary restrictions are at odds with the treatment guidelines of the American Diabetes Association (ADA) and the Eighth Joint National Committee (JNC 8). ADA and JNC 8 equally recommend the prescription of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for hypertensive patients with type 2 diabetes mellitus (T2DM) with overt proteinuria (urine albumin to creatinine ratio (UACR) ≥ 300 mg/g creatinine). However, since 1 April 2018, Indonesian formulary restricted telmisartan and valsartan only for T2DM patients with declined renal function as shown by eGFR value. There is no compelling evidence in favor of ACEI over ARB or vice versa except for data supporting the early use of both drugs in patients with overt proteinuria. However, ARB is a choice if ACEI's side effects, that is, coughing, occurs. Therefore, it necessitates a detailed evaluation of the effects of ACEIs and ARBs on albuminuria and their side effect, hyperkalemia, specific to Indonesian T2DM patients. This cross-sectional study involved 134 T2DM patients whose treatment was restricted to either ACEIs ( T2DM patients in the ACEI and ARB groups had similar characteristics except for a higher body mass index ( This cross-sectional study demonstrated that ACEIs and ARBs have a similar effect on albuminuria and hyperkalemia in Indonesian hypertensive T2DM patients, even after correction for potentially confounding variables.
Identifiants
pubmed: 32802494
doi: 10.1155/2020/5342161
pmc: PMC7414342
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5342161Informations de copyright
Copyright © 2020 Putri S. Agustina et al.
Déclaration de conflit d'intérêts
The authors claim no conflicts of interest while preparing, conducting, or reporting this study.
Références
Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006257
pubmed: 17054288
Vascul Pharmacol. 2013 Apr;58(4):259-71
pubmed: 23313806
Diabetes Care. 2016 Dec;39(12):2218-2224
pubmed: 27872156
Drugs Context. 2013 Mar 27;2013:212249
pubmed: 24432038
Kidney Int. 2009 May;75(10):1006-8
pubmed: 19404281
N Engl J Med. 2004 Aug 5;351(6):585-92
pubmed: 15295051
Diabetes Care. 2017 Jan;40(Suppl 1):S4-S5
pubmed: 27979887
Am Fam Physician. 2015 Sep 15;92(6):487-95
pubmed: 26371733
Medicine (Baltimore). 2015 Sep;94(39):e1560
pubmed: 26426627
Blood Press. 2013 Jun;22(3):158-64
pubmed: 23244371
Diabetes Obes Metab. 2007 Nov;9(6):799-812
pubmed: 17924864
Vasc Health Risk Manag. 2009;5(1):129-40
pubmed: 19436679
Health Technol Assess. 2014 Feb;18(14):1-128
pubmed: 24576414
N Engl J Med. 2004 Nov 4;351(19):1952-61
pubmed: 15516696
Kidney Blood Press Res. 2017;42(2):358-368
pubmed: 28618426
Int J Cardiol. 2015 Mar 1;182:250-7
pubmed: 25585359
CMAJ. 2013 Aug 6;185(11):949-57
pubmed: 23798459
Clin Chem. 2003 Jan;49(1):190-2
pubmed: 12507983
Kidney Int. 2008 Aug;74(3):364-9
pubmed: 18496508
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130